CAR-T Therapies Show Promise in Treating Autoimmune Disorders
Experimental CAR-T therapies developed by Cabaletta Bio and Bristol Myers Squibb have shown potential in inducing complete remissions in patients suffering from severe inflammatory muscle diseases. Results from dual clinical…